Compare UCL & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UCL | IXHL |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.8M | 45.0M |
| IPO Year | 2019 | 2024 |
| Metric | UCL | IXHL |
|---|---|---|
| Price | $1.40 | $2.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.4K | ★ 652.3K |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.11 |
| 52 Week High | $4.19 | $6.39 |
| Indicator | UCL | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 48.46 |
| Support Level | $1.23 | $0.34 |
| Resistance Level | $1.67 | $3.68 |
| Average True Range (ATR) | 0.08 | 0.32 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 45.90 | 18.49 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.